Bilateral facial cutaneous angiomyolipomas: First case in the literature and a possible correlation with human immunodeficiency virus

Braganza, Joshua; Aljwaid, Ahmed; Al-Azzawi, Mohammed; Alshami, Abbas; Patel, Nitin

doi:10.1016/j.idcr.2020.e00909

Cited by 2 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A similar case was reported regarding a female who switched from TDF/FTC/EFV to TAF/FTC/BIC and 18 months later developed bilateral facial angiomyolipomas. 9 The diagnosis was made on computed tomography as the patient refused a biopsy. As there was no de nitive pathologic diagnosis and angiolipoma and angiomyolipomas may be di cult to differentiate, 10 .…”

Section: Discussionmentioning

confidence: 99%

Angiolipoma associated with antiretroviral switch therapy: A Case Report

Taylor,

Pandit

2024

Preprint

View full text Add to dashboard Cite

Background Angiolipomas have been well described in patients with HIV exposed to protease inhibitors with possible resolution after switching to non-nucleoside reverse transcriptase inhibitor-based regimens. Resolution of symptoms have occurred with switches to non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens; however, little is known regarding the development of angiolipomas when switching from NNRTI- to modern, integrase strand transfer inhibitor-based regimens. We describe a patient who underwent switch therapy from tenofovir disoproxil fumarate/emtricitabine/efavirenz (TDF/FTC/EFV) to tenofovir alafenamide/FTC/bictegravir (TAF/FTC/BIC) who later developed angiolipomas. Case Presentation: A 55-year-old male had been on TDF/FTC/EFV for 8 years before switching to TAF/FTC/BIC. Nineteen months after antiretroviral switch, the patient presented with multiple lesions in the upper extremities and abdomen. Diagnostic biopsies revealed non-encapsulated angiolipomas and HHV-8 and non-alcoholic fatty liver disease was ruled out. New lesions continued to appear 29 months after ART switch, after which now lesions appeared and prior lesions remained stable with no increase in size noted. No surgical intervention or change in antiretroviral therapy was needed. Conclusions Angiogenesis may have been suppressed with TDF/FTC/EFV treatment, however when switched to TAF/FTC/BIC, promoted the growth of angiolipomas. Clinicians should be aware of the impact of switching to modern ART therapies resulting in possible adipogenesis.

show abstract

Section: Discussionmentioning

confidence: 99%

Angiolipoma associated with antiretroviral switch therapy: A Case Report

Taylor,

Pandit

2024

Preprint

View full text Add to dashboard Cite

show abstract

Angiolipoma associated with antiretroviral switch therapy: a case report

Taylor,

Pandit

2024

AIDS Res Ther

View full text Add to dashboard Cite

Background Angiolipomas have been well described in patients with HIV exposed to protease inhibitors with possible resolution after switching to non-nucleoside reverse transcriptase inhibitor-based regimens. Resolution of symptoms have occurred with switches to non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens; however, little is known regarding the development of angiolipomas when switching from NNRTI- to modern, integrase strand transfer inhibitor-based regimens. We describe a patient who underwent switch therapy from tenofovir disoproxil fumarate/emtricitabine/efavirenz (TDF/FTC/EFV) to tenofovir alafenamide/FTC/bictegravir (TAF/FTC/BIC) who later developed angiolipomas. Case Presentation A 55-year-old male had been on TDF/FTC/EFV for 8 years before switching to TAF/FTC/BIC. Nineteen months after antiretroviral switch, the patient presented with multiple lesions in the upper extremities and abdomen. Diagnostic biopsies revealed non-encapsulated angiolipomas and HHV-8 and non-alcoholic fatty liver disease was ruled out. New lesions continued to appear 29 months after ART switch, after which now lesions appeared and prior lesions remained stable with no increase in size noted. No surgical intervention or change in antiretroviral therapy was needed. Conclusions Angiogenesis may have been suppressed with TDF/FTC/EFV treatment, however when switched to TAF/FTC/BIC, promoted the growth of angiolipomas. Clinicians should be aware of the impact of switching to modern ART therapies resulting in possible adipogenesis.

show abstract

Bilateral facial cutaneous angiomyolipomas: First case in the literature and a possible correlation with human immunodeficiency virus

Cited by 2 publications

References 19 publications

Angiolipoma associated with antiretroviral switch therapy: A Case Report

Angiolipoma associated with antiretroviral switch therapy: A Case Report

Angiolipoma associated with antiretroviral switch therapy: a case report

Contact Info

Product

Resources

About